A patient who is taking rimonabant, a weight loss drug, runs a higher risk of experiencing severe psychiatric events, such as depression and anxiety
The researchers found that׃
- The rimonabant patients lost 4.7kg more than the placebo patients after one year
- The rimonabant patients ran a 40% higher risk of experiencing adverse events or serious adverse events, compared to the placebo patients
- The rimonabant patients ran 2.5 times the risk of discontinuing treatment because of depression, compared to the placebo patients
- The rimonabant patients ran 3.5 times the risk of discontinuing treatment due to anxiety, compared to the placebo patients
Posts
